Metabolic reprogramming of human cells in response to oxidative stress: Implications in the pathophysiology and therapy of mitochondrial diseases

Current Pharmaceutical Design

Volumn 20, Issue 35, 2014, Pages 5510-5526

  Wu, Yu Ting ^a   Wu, Shi Bei ^a   Wei, Yau Huei ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b MACKAY MEDICAL COLLEGE   (Taiwan)

Author keywords

AMPK; Antioxidant enzyme; Metabolic adaptation; Mitochondrial disease; MtDNA mutation; Oxidative stress; Sirtuin

Indexed keywords

ANTIOXIDANT; CARNITINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MITOCHONDRIAL DNA; RESVERATROL; SIRTUIN 1; SIRTUIN 3; UBIDECARENONE; REACTIVE OXYGEN METABOLITE;

ANAEROBIC GLYCOLYSIS; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CALCIUM HOMEOSTASIS; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; HUMAN; KETOGENIC DIET; LONG TERM CARE; MITOCHONDRIAL MYOPATHY; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ACETYLATION; SUPPLEMENTATION; UPREGULATION; ANIMAL; DRUG EFFECTS; ENERGY METABOLISM; METABOLISM; MITOCHONDRIAL DISEASES; MITOCHONDRION; PHYSIOLOGY;

ANIMALS; ANTIOXIDANTS; APOPTOSIS; ENERGY METABOLISM; HUMANS; MITOCHONDRIA; MITOCHONDRIAL DISEASES; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 84925863716     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666140306103401     Document Type: Article

References (229)

1. [1] Koopman WJ, Distelmaier F, Smeitink JA, Willems PH. OXPHOS mutations and neurodegeneration. EMBO J 2013; 32: 9-29.
2. [2] Schon EA, DiMauro S, Hirano M. Human mitochondrial DNA: roles of inherited and somatic mutations. Nat Rev Genet 2012; 13: 878-90.
3. [3] Vafai SB, Mootha VK. Mitochondrial disorders as windows into an ancient organelle. Nature 2012; 491: 374-83.
4. [4] Kann O, Kovács R. Mitochondria and neuronal activity. Am J Physiol Cell Physiol 2007; 292: 641-57.
5. [5] Mitsui T, Kawai H, Nagasawa M, et al. Oxidative damage to skeletal muscle DNA from patients with mitochondrial encephalomyopathies. J Neurol Sci 1996; 139: 111-6.
6. [6] Morán M, Moreno-Lastres D, Marín-Buera L, et al. Mitochondrial respiratory chain dysfunction: implications in neurodegeneration. Free Radic Biol Med 2012; 53: 595-609.
7. MITOMAP: a human mitochondrial genome database. Available from http://www.mitomap.org/MITOMAP.
8. [8] Folbergrová J, Kunz WS. Mitochondrial dysfunction in epilepsy. Mitochondrion 2012; 12: 35-40.
9. [9] Mitsui T, Umaki Y, Nagasawa M, et al. Mitochondrial damage in patients with long-term corticosteroid therapy: development of oculoskeletal symptoms similar to mitochondrial disease. Acta Neuropathol 2002; 104: 260-6.
10. [10] Katayama Y, Maeda K, Iizuka T, et al. Accumulation of oxidative stress around the stroke-like lesions of MELAS patients. Mitochondrion 2009; 9: 306-13.
11. [11] Yen MY, Kao SH, Wang AG, Wei YH. Increased 8-hydroxy-2'-deoxyguanosine in leukocyte DNA in Leber's hereditary optic neuropathy. Invest Ophthalmol Vis Sci 2004; 45: 1688-91.
12. [12] Mitsui T, Kawai H, Nagasawa M, et al. Oxidative damage to skeletal muscle DNA from patients with mitochondrial encephalomyopathies. J Neurol Sci 1996; 139: 111-6.
13. [13] Menzies KJ, Robinson BH, Hood DA. Effect of thyroid hormone on mitochondrial properties and oxidative stress in cells from patients with mtDNA defects. Am J Physiol Cell Physiol 2009; 296: 355-62.
14. [14] Lu CY, Wang EK, Lee HC, et al. Increased expression of manganese-superoxide dismutase in fibroblasts of patients with CPEO syndrome. Mol Genet Metab 2003; 80: 321-9.
15. [15] van Eijsden RG, Eijssen LM, Lindsey PJ, et al. Termination of damaged protein repair defines the occurrence of symptoms in carriers of the mt 3243 A to G tRNALeu mutation. J Med Genet 2008; 45: 525-34.
16. [16] Majora M, Wittkampf T, Schuermann B, et al. Functional consequences of mitochondrial DNA deletions in human skin fibroblasts: increased contractile strength in collagen lattices is due to oxidative stress-induced lysyl oxidase activity. Am J Pathol 2009; 175: 1019-29.
17. [17] Piccolo G, Banfi P, Azan G, et al. Biological markers of oxidative stress in mitochondrial myopathies with progressive external ophthalmoplegia. J Neurol Sci 1991; 105: 57-60.
18. [18] Pitkänen S, Raha S, Robinson BH. Diagnosis of complex I deficiency in patients with lactic acidemia using skin fibroblast cultures. Biochem Mol Med 1996; 59: 134-7.
19. [19] Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007; 87: 99-163.
20. [20] Galluzzi L, Kepp O, Trojel-Hansen C, Kroemer G. Mitochondrial control of cellular life, stress, and death. Circ Res 2012; 111: 1198-207.
21. [21] Cotán D, Cordero MD, Garrido-Maraver J, et al. Secondary Coenzyme Q10 deficiency triggers mitochondria degradation by mitophagy in MELAS fibroblasts. FASEB J 2011; 25: 2669-87.
22. [22] Chen CY, Chen HF, Gi SJ, et al. Decreased heat shock protein 27 expression and altered autophagy in human cells harboring A8344G mitochondrial DNA mutation. Mitochondrion 2011; 11: 739-49.
23. [23] King MP, Attadi G. Mitochondria-mediated transformation of human rho0 cells. Methods Enzymol 1996; 264: 313-34.
24. [24] Yoneda M, Miyatake T, Attardi, G. Complementation of mutant and wild-type human mitochondrial DNAs coexisting since the mutation event and lack of complementation of DNAs introduced separately into a cell within distinct organelles. Mol Cell Biol 1994; 14: 2699-712.
25. [25] King MP, Attardi G. Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science 1989; 246: 500-3.
26. [26] Swerdlow, RH. Mitochondria in cybrids containing mtDNA from persons with mitochondriopathies. J Neurosci Res 2007; 85: 3416-28.
27. [27] Peng TI, Yu PR, Chen JY, et al. Visualizing common deletion of mitochondrial DNA-augmented mitochondrial reactive oxygen species generation and apoptosis upon oxidative stress. Biochim Biophys Acta 2006; 1762: 241-55.
28. [28] Pello R, Martín MA, Carelli V, et al. Mitochondrial DNA background modulates the assembly kinetics of OXPHOS complexes in a cellular model of mitochondrial disease. Hum Mol Genet 2008; 17: 4001-11.
29. [29] Wu SB, Ma YS, Wu YT, et al. Mitochondrial DNA mutationelicited oxidative stress, oxidative damage, and altered gene expression in cultured cells of patients with MERRF syndrome. Mol Neurobiol 2010; 41: 256-66.
30. [30] Ferrer I. Altered mitochondria, energy metabolism, voltagedependent anion channel, and lipid rafts converge to exhaust neurons in Alzheimer's disease. J Bioenerg Biomembr 2007; 41: 425-31.
31. [31] Osman C, Merkwirth C, Langer T. Prohibitins and the functional compartmentalization of mitochondrial membranes. J Cell Sci 2009; 122: 3823-30.
32. [32] Liu CY, Lee CF, Wei YH. Quantitative effect of 4977 bp deletion of mitochondrial DNA on the susceptibility of human cells to UVinduced apoptosis. Mitochondrion 2007; 7: 89-95.
33. [33] Ikezoe K, Nakagawa M, Yan C, et al. Apoptosis is suspended in muscle of mitochondrial encephalomyopathies. Acta Neuropathol 2002; 103: 531-40.
34. [34] Auré K, Fayet G, Leroy JP, et al. Apoptosis in mitochondrial myopathies is linked to mitochondrial proliferation. Brain 2006; 129: 1249-59.
35. [35] Liu CY, Lee CF, Wei YH. Activation of PKCdelta and ERK1/2 in the sensitivity to UV-induced apoptosis of human cells harboring 4977 bp deletion of mitochondrial DNA. Biochim Biophys Acta 2009; 1792: 783-90.
36. [36] Umaki Y, Mitsui T, Endo I, et al. Apoptosis-related changes in skeletal muscles of patients with mitochondrial diseases. Acta Neuropathol 2002; 103: 163-70.
37. [37] Kujoth GC, Hiona A, Pugh TD, et al. Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. Science 2005; 309: 481-4.
38. [38] Chuang YC, Lin JW, Chen SD, et al. Preservation of mitochondrial integrity and energy metabolism during experimental status epilepticus leads to neuronal apoptotic cell death in the hippocampus of the rat. Seizure 2009; 18: 420-8.
39. [39] Feissner RF, Skalska J, Gaum WE, Sheu SS. Crosstalk signaling between mitochondrial Ca2+ and ROS. Front Biosci 2009; 14: 1197-218.
40. [40] Gunter TE, Yule DI, Gunter KK, et al. Calcium and mitochondria. FEBS Lett 2004; 567: 96-102.
41. Nicholls DG. Mitochondria and calcium signaling. Cell Calcium 2005; 38: 311-7. Review.
42. [42] Dykens JA. Isolated cerebral and cerebellar mitochondria produce free radicals when exposed to elevated Ca2+ and Na+: implications for neurodegeneration. J Neurochem 1994; 63: 584-91.
43. [43] Willems PH, Valsecchi F, Distelmaier F, et al. Mitochondrial Ca2+ homeostasis in human NADH: ubiqinone oxidoreductase deficiency. Cell Calcium 2008; 44: 123-33.
44. [44] Kubota M, Kasahara T, Nakamura T, et al. Abnormal Ca2+ dynamics in transgenic mice with neuron-specific mitochondrial DNA defects. J Neurosci 2006; 26: 12314-24.
45. [45] Brini M, Pinton P, King MP, et al. A calcium signaling defect in the pathogenesis of a mitochondrial DNA inherited oxidative phosphorylation deficiency. Nat Med 1999; 5: 951-4.
46. [46] Moudy AM, Handran SD, Godberg MP, et al. Abnormal calcium homeostasis and mitochondrial polarization in a human encephalomyopathy. Proc Natl Acad Sci USA 1995; 92: 729-33.
47. [47] Federico A, Cardaioli E, Da Pozzo P, et al. Mitochondria, oxidative stress and neurodegeneration. J Neurol Sci 2012; 322: 254-62.
48. [48] Werth JL, Thayer SA. Mitochondria buffer physiological calcium loads in cultured rat dorsal root ganglion neurons. J Neurosci 1994; 14: 348-56.
49. [49] Crawford DR, Davies KJ. Adaptive response and oxidative stress. Environ Health Perspect 1994; 10: 25-8.
50. [50] Gort AS, Imlay JA. Balance between endogenous superoxide stress and antioxidant defenses. J Bacteriol 1998; 180: 1402-10.
51. [51] Ohkoshi N, Mizusawa H, Shiraiwa N, et al. Superoxide dismutases of muscle in mitochondrial encephalomyopathies. Muscle Nerve 1995; 18: 1265-71.
52. [52] Rusanen H, Majamaa K, Hassinen IE. Increased activities of antioxidant enzymes and decreased ATP concentration in cultured myoblasts with the 3243A to G mutation in mitochondrial DNA. Biochim Biophys Acta 2000; 1500: 10-6.
53. [53] Robinson BH. The role of manganese superoxide dismutase in health and disease. J Inherit Metab Dis 1998; 21: 598-603.
54. [54] Filosto M, Tonin P, Vattemi G, et al. Antioxidant agents have a different expression pattern in muscle fibers of patients with mitochondrial diseases. Acta Neuropathol 2002; 103: 215-20.
55. [55] Qi X, Lewin AS, Hauswirth WW, et al. Optic neuropathy induced by reductions in mitochondrial superoxide dismutase. Invest Ophthalmol Vis Sci 2003; 44: 1088-96.
56. [56] Vives-Bauza C, Gonzalo R, Manfredi G, et al. Enhanced ROS production and antioxidant defenses in cybrids harbouring mutations in mtDNA. Neurosci Lett 2006: 391: 136-41.
57. [57] Brambilla L, Cairo G, Sestili P, et al. Mitochondrial respiratory chain deficiency leads to overexpression of antioxidant enzymes. FEBS Lett 1997; 418: 247-50.
58. [58] Wei YH, Lu CY, Wei CY, et al. Oxidative stress in human aging and mitochondrial disease-consequences of defective mitochondrial respiration and impaired antioxidant enzyme system. Chin J Physiol 2001; 44: 1-11.
59. [59] Jazwinski SM. The retrograde response: when mitochondrial quality control is not enough. Biochim Biophys Acta 2013; 1833: 400-9.
60. [60] Cabello A, Navarro C, Ricoy JR. Morphological changes of mitochondrial myopathies. Rev Neurol 1998; 26: S44-49.
61. [61] Wojewoda M, Duszy_ski J, Szczepan owska J. NARP mutation and mtDNA depletion trigger mitochondrial biogenesis which can be modulated by selenite supplementation. Int J Biochem Cell Biol 2011; 43: 1178-86.
62. [62] Heddi A, Lestienne P, Wallace DC, Stepien G. Mitochondrial DNA expression in mitochondrial myopathies and coordinated expression of nuclear genes involved in ATP production. J Biol Chem 1993; 268: 12156-63.
63. [63] Jones AW, Yao Z, Vicencio JM, et al. PGC-1 family coactivators and cell fate: roles in cancer, neurodegeneration, cardiovascular disease and retrograde mitochondria-nucleus signalling. Mitochondrion 2012; 12: 86-99.
64. [64] Heddi A, Stepien G, Benke PJ, Wallace DC. Coordinate induction of energy gene expression in tissues of mitochondrial disease patients. J Biol Chem 1999; 274: 22968-76.
65. [65] Miceli MV, Jazwinski SM. Common and cell type-specific responses of human cells to mitochondrial dysfunction. Exp Cell Res 2005; 302: 270-80.
66. [66] von Kleist-Retzow JC, Hornig-Do HT, Schauen M, et al. Impaired mitochondrial Ca2+ homeostasis in respiratory chain-deficient cells but efficient compensation of energetic disadvantage by enhanced anaerobic glycolysis due to low ATP steady state levels. Exp Cell Res 2007; 313: 3076-89.
67. [67] Le Goffe C, Vallette G, Charrier L, et al. Metabolic control of resistance of human epithelial cells to H2O2 and NO stresses. Biochem J 2002; 364: 349-59.
68. [68] Kalinina EV, Chernov NN, Saprin AN. Involvement of thio-, peroxi-, and glutaredoxins in cellular redox-dependent processes. Biochemistry 2008; 73: 1493-510.
69. [69] Myers JM, Myers CR. The effects of hexavalent chromium on thioredoxin reductase and peroxiredoxins in human bronchial epithelial cells. Free Radic Biol Med 2009; 47: 1477-85.
70. [70] Wu SB, Wei YH. AMPK-mediated increase of glycolysis as an adaptive response to oxidative stress in human cells: implication of the cell survival in mitochondrial diseases. Biochim Biophys Acta 2012; 1822: 233-47.
71. [71] Kondoh H. Cellular life span and the Warburg effect. Exp Cell Res 2008; 314: 1923-8.
72. [72] Cantó C, Auwerx J. AMP-activated protein kinase and its downstream transcriptional pathways. Cell Mol Life Sci 2010; 67: 3407-23.
73. [73] Han Y, Wang Q, Song P, et al. Redox regulation of the AMPactivated protein kinase. PLoS One 2010; 5: e15420.
74. [74] Fu J, Jin J, Cichewicz RH, et al. Trans-()-Viniferin increases mitochondrial sirtuin 3 (SIRT3), activates AMP-activated protein kinase (AMPK), and protects cells in models of Huntington’s disease. J Biol Chem 2012; 287: 24460-72.
75. [75] Vingtdeux V, Giliberto L, Zhao H, et al. AMPactivated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. J Biol Chem 2010; 285: 9100-13.
76. [76] Vingtdeux V, Davies P, Dickson DW, Marambaud P. AMPK is abnormally activated in tangle-and pre-tangle-bearing neurons in Alzheimer's disease and other tauopathies. Acta Neuropathol 2011; 121: 337-49.
77. [77] Salminen A, Kaarniranta K. AMP-activated protein kinase (AMPK) controls the aging process via an integrated signaling network. Ageing Res Rev 2012; 11: 230-41.
78. [78] Mackenzie RM, Salt IP, Miller WH, et al. Mitochondrial reactive oxygen species enhance AMP-activated protein kinase activation in the endothelium of patients with coronary artery disease and diabetes. Clin Sci (Lond) 2013; 124: 403-11.
79. [79] Kukidome D, Nishikawa T, Sonoda K, et al. Activation of AMPactivated protein kinase reduces hyperglycemia-induced mitochon drial reactive oxygen species production and promotes mitochondrial biogenesis in human umbilical vein endothelial cells. Diabetes 2006; 55: 120-7.
80. [80] Hou X, Song J, Li XN, et al. Metformin reduces intracellular reactive oxygen species levels by upregulating expression of the antioxidant thioredoxin via the AMPK-FOXO3 pathway. Biochem Biophys Res Commun 2010; 396: 199-205.
81. [81] Colombo SL, Moncada S. AMPK-alpha1 regulates the antioxidant status of vascular endothelial cells. Biochem J 2009; 421: 163-9.
82. [82] Calegari VC, Zoppi CC, Rezende LF, et al. Endurance training activates AMP-activated protein kinase, increases expression of uncoupling protein 2 and reduces insulin secretion from rat pancreatic islets. J Endocrinol 2011; 208: 257-64.
83. [83] Wang S, Dale GL, Song P, et al. AMPKalpha1 deletion shortens erythrocyte life span in mice: role of oxidative stress. J Biol Chem 2010; 285: 19976-85.
84. [84] Ma YS, Chen YC, Lu CY, Liu CY, Wei YH. Upregulation of matrix metalloproteinase 1 and disruption of mitochondrial network in skin fibroblasts of patients with MERRF syndrome. Ann NY Acad Sci 2005; 1042: 55-63.
85. [85] Biswas G, Adebanjo OA, Freedman BD, et al. Retrograde Ca2+ signaling in C2C12 skeletal myocytes in response to mitochondrial genetic and metabolic stress: a novel mode of inter-organelle crosstalk. EMBO J 1999; 18: 522-33.
86. [86] Jazwinski SM. The retrograde response: when mitochondrial quality control is not enough. Biochim Biophys Acta 2013; 1833: 400-9.
87. [87] Finley LW, Haigis MC. The coordination of nuclear and mitochondrial communication during aging and calorie restriction. Ageing Res Rev 2009; 8: 173-88.
88. [88] Scarpulla RC. Transcriptional paradigms in mammalian mitochondrial biogenesis and function. Physiol Rev 2008; 88: 611-38.
89. [89] Mellstrom B, Savignac M, Gomez-Villafuertes R, Naranjo JR. Ca2+-operated transcriptional networks: molecular mechanisms and in vivo models. Physiol Rev 2008; 88: 421-49.
90. [90] Rohas LM, St-Pierre J, Uldry M, et al. A fundamental system of cellular energy homeostasis regulated by PGC-1alpha. Proc Natl Acad Sci USA 2007; 104: 7933-38.
91. [91] Scarpulla, RC. Tanscriptional paradigms in mammalian mitochondrial biogenesis and function. Physiol Rev 2008; 88: 611-38.
92. [92] Biswas G, Tang W, Sondheimer W, et al. A distinctive physiological role for IkappaBbeta in the propagation of mitochondrial respiratory stress signaling. J Biol Chem 2008; 283: 12586-94.
93. [93] Amuthan G, Biswas G, Ananadatheerthavarada HK, et al. Mitochondrial stress-induced calcium signaling, phenotypic changes and invasive behavior in human lung carcinoma A549 cells. Oncogene 2002; 2: 7839-49.
94. [94] Amuthan G, Biswas G, Zhang SY, et al. Mitochondria-to-nucleus stress signaling induces phenotypic changes, tumor progression and cell invasion. EMBO J 2001; 20: 1910-20.
95. [95] Lee CF, Chen YC, Liu CY, Wei YH. Involvement of protein kinase C delta in the alteration of mitochondrial mass in human cells under oxidative stress. Free Radic Biol Med 2006; 40: 2136-46.
96. [96] Arnould T, Vankoningsloo S, Renard P, et al. CREB activation induced by mitochondrial dysfunction is a new signaling pathway that impairs cell proliferation. EMBO J 2002; 21: 53-63.
97. [97] Wei YH, Lee CF, Lee HC, et al. Increases of mitochondrial mass and mitochondrial genome in association with enhanced oxidative stress in human cells harboring 4,977 bp-deleted mitochondrial DNA. Ann NY Acad Sci 2001; 928: 97-12.
98. [98] Lee HC, Yin PH, Chi CW, Wei YH. Increase in mitochondrial mass in human fibroblasts under oxidative stress and during replicative cell senescence. J Biomed Sci 2002; 9: 517-26.
99. [99] Jones AW, Yao Z, Vicencio JM, et al. PGC-1 family coactivators and cell fate: Roles in cancer, neurodegeneration, cardiovascular disease and retrograde mitochondria-nucleus signaling. Mitochondrion 2012; 12: 86-99.
100. [100] Cunningham JT, Rodgers JT, Arlow DH, et al. mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature 2007; 450: 736-40.
101. [101] Handschin C, Spiegelman BM. Peroxisome proliferator-activated receptor gamma coactivator 1, energy homeostasis, and metabolism. Endocr Rev 2006; 27: 728-35.
102. [102] Psarra AM, Sekeris CE. Steroid and thyroid hormone receptors in mitochondria. IUBMB Life 2008; 60: 210-23.
103. [103] Lee SR, Kim HK, Song IS, et al. Glucocorticoids and their receptors: Insights into specific roles in mitochondria. Prog Biophys Mol Biol 2013; 112: 44-54.
104. [104] Psarra AM, Sekeris CE. Glucocorticoids induce mitochondrial gene transcription in HepG2 cells: role of the mitochondrial glucocorticoid receptor. Biochim Biophys Acta 2011; 1813: 1814-21.
105. [105] Jager S, Handschin C, St-Pierre J, Spiegelman BM. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc Natl Acad Sci USA 2007; 104: 12017-22.
106. [106] Olson BL, Hock MB, Ekholm-Reed S, et al. SCFCdc4 acts antagonistically to the PGC-1alpha transcriptional coactivator by targeting it for ubiquitin-mediated proteolysis. Genes Dev 2008; 22: 252-64.
107. [107] Rodgers JT, Lerin C, Haas W, et al. Nutrient control of glucose homeostasis through a complex of PGC-1_ and SIRT1. Nature 2005; 434: 113-8.
108. [108] Suwa M, Nakano H, Kumagai S. Effects of chronic AICAR treatment on fiber composition, enzyme activity, UCP3, and PGC-1 in rat muscles. J Appl Physiol 2003; 95: 960-8.
109. [109] Polevoda B, Sherman F. The diversity of acetylated proteins. Genome Biol 2002; 3: 1-6.
110. [110] Yang XY, Grégoire S. Metabolism, cytoskeleton and cellular signaling in the grip of protein N-and O-acetylation. EMBO Rep 2007; 8: 556-62.
111. [111] Longo VD, Kennedy BK. Sirtuins in aging and age-related disease. Cell 2006; 126: 257-68.
112. [112] Dali-Youcef N, Lagouge M, Froelich S, et al. Sirtuins: the 'magnificent seven', function, metabolism and longevity. Ann Med 2007; 39: 335-45.
113. [113] Guarente L. Sirtuins as potential targets for metabolic syndrome. Nature 2006; 444: 868-74.
114. [114] Motta MC, Divecha N, Lemieux M, et al. Mammalian SIRT1 represses forkhead transcription factors. Cell 2004; 116: 551-63.
115. [115] Chen D, Steele AD, Lindquist S, Guarente L. Increase in activity during calorie restriction requires Sirt1. Science 2005; 310: 1641.
116. [116] Cohen HY, Miller C, Bitterman KJ, et al. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 2004; 305: 390-2.
117. [117] Civitarese AE, Carling S, Heilbronn LK, et al. Calorie restriction increases muscle mitochondrial biogenesis in healthy humans. PLoS Med 2007; 4: e76.
118. [118] Lagouge M, Argmann C, Gerhart-Hines Z. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1_. Cell 2006; 127: 1109-22.
119. [119] Gerhart-Hines Z, Rodgers JT, Bare O, et al. Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1_. EMBO J 2007; 26: 1913-23.
120. [120] Nemoto S, Fergusson MM, Finkel T. SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1_. J Biol Chem 2005; 280: 16456-60.
121. [121] Bordone L, Guarente L. Calorie restriction, SIRT1 and metabolism: understanding longevity. Nat Rev Mol Cell Biol 2005; 6: 298-305.
122. [122] Nasrin N, Kaushik VK, Fortier E, et al. JNK1 phosphorylates SIRT1 and promotes its enzymatic activity. PLoS One 2009; 4: e8414.
123. [123] Wu YT, Wu SB, Lee WY, Wei YH. Mitochondrial respiratory dysfunction-elicited oxidative stress and posttranslational protein modification in mitochondrial diseases. Ann NY Acad Sci 2010; 1201: 147-56.
124. [124] Voets AM, Lindsey PJ, Vanherle SJ, et al. Patient-derived fibroblasts indicate oxidative stress status and may justify antioxidant therapy in OXPHOS disorders. Biochim Biophys Acta 2012; 1817: 1971-8.
125. [125] Brunet A, Sweeney LB, Sturgill JF, et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004; 303: 2011-15.
126. [126] de Oliveira RM, Pais TF, Outeiro TF. Sirtuin: Common targets in aging and in neurodegeneration. Current Drug Targets 2010; 11: 1270-80.
127. [127] Greer EL, Brunet A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 2005; 24: 7410-25.
128. [128] Bordone L, Motta MC, Picard F, et al. Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic beta cells. PLoS Biol 2006; 4: e31.
129. [129] Olmos Y, Sánchez-Gómez FJ, Wild B, et al. SirT1 regulation of antioxidant genes is dependent on the formation of a FOXO3a/PGC-1_ complex. Antioxid Redox Signal 2013; 19: 1507-21.
130. [130] Yun JM, Chien A, Jialal I, Devaraj S. Resveratrol up-regulates SIRT1 and inhibits cellular oxidative stress in the diabetic milieu: mechanistic insights. J Nutr Biochem 2012; 23: 699-705.
131. [131] Dillon LM, Hida A, Garcia S, et al. Long-term bezafibrate treatment improves skin and spleen phenotypes of the mtDNA mutator mouse. PLoS One 2012; 7: e44335.
132. [132] Lombard DB, Alt FW, Cheng HL, et al. Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation. Mol Cell Biol 2007; 27: 8807-14.
133. [133] Hirschey MD, Shimazu T, Goetzman E, et al. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature 2010; 464: 121-5.
134. [134] Ahn BH, Kim HS, Song S, et al. A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis. Proc Natl Acad Sci USA 2008; 105: 14447-52.
135. [135] Finley LW, Haas W, Desquiret-Dumas V, et al. Succinate dehydrogenase is a direct target of sirtuin 3 deacetylase activity. PLoS One 2011; 6: e23295.
136. [136] Wu YT, Lee HC, Liao CC, Wei YH. Regulation of mitochondrial FoF1ATPase activity by Sirt3-catalyzed deacetylation and its deficiency in human cells harboring 4977 bp deletion of mitochondrial DNA. Biochim Biophys Acta 2013; 1832: 216-27.
137. [137] Jing E, Emanuelli B, Hirschey MD, et al. Sirtuin-3 (Sirt3) regulates skeletal muscle metabolism and insulin signaling via altered mitochondrial oxidation and reactive oxygen species production. Proc Nat Acad Sci USA 2011; 108: 14608-13.
138. [138] Bhakat KK, Mokkapati SK, Boldogh I, et al. Acetylation of human 8-oxoguanine-DNA glycosylase by p300 and its role in 8-oxoguanine repair in vivo. Mol Cell Biol 2006; 26: 1654-65.
139. [139] Shulga N, Wilson-Smith R, Pastorino JG. Sirtuin-3 deacetylation of cyclophilin D induces dissociation of hexokinase II from the mitochondria. J Cell Sci 2009; 123: 894-02.
140. [140] Jing E, Emanuelli B, Hirschey MD, et al. Sirtuin-3 (Sirt3) regulates skeletal muscle metabolism and insulin signaling via altered mitochondrial oxidation and reactive oxygen species production. Proc Natl Acad Sci USA 2011; 108: 14608-13.
141. [141] Tauriainen E, Luostarinen M, Martonen E, et al. Distinct effects of calorie restriction and resveratrol on diet-induced obesity and fatty liver formation. J Nutr Metab 2011; 2011: 525094.
142. [142] Hallows WC, Yu W, Smith BC, et al. Sirt3 promotes the urea cycle and fatty acid oxidation during dietary restriction. Mol Cell 2011; 41: 139-49.
143. [143] Someya S, Yu W, Hallows WC, et al. Sirt3 mediates reduction of oxidative damage and prevention of age-related hearing loss under caloric restriction. Cell 2010; 143: 802-12.
144. [144] Qiu X, Brown K, Hirschey MD, et al. Calorie restriction reduces oxidative stress by SIRT3-mediated SOD2 activation. Cell Metab 2010; 12: 662-7.
145. [145] Tao R, Coleman MC, Pennington JD, et al. Sirt3-mediated deacetylation of evolutionarily conserved lysine 122 regulates MnSOD activity in response to stress. Mol Cell 2010; 40: 893-04.
146. [146] Lanza IR, Short DK, Short KR, et al. Endurance exercise as a countermeasure for aging. Diabetes 2008; 57: 2933-42.
147. [147] Yechoor VK, Patti ME, Ueki K, et al. Distinct pathways of insulinregulated versus diabetes-regulated gene expression: an in vivo analysis in MIRKO mice, Proc Natl Acad Sci USA 204; 101: 16525-30.
148. [148] Sundaresan NR, Gupta M, Kim G, et al. Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice. J Clin Invest 2009; 119: 2758-71.
149. [149] Pillai VB, Sundaresan NR, Kim G, et al. Exogenous NAD+ blocks cardiac hypertrophic response via activation of the SIRT3-LJB1-AMP-activated kinase pathway. J Biol Chem 2010; 285: 3133-44.
150. [150] Pillai VB, Sundaresan NR, Jeevanandam V, Gupta MP. Mitochondrial SIRT3 and heart disease. Cardiovasc Res 2010; 88: 250-6.
151. [151] D'Aquila P, Rose G, Panno ML, et al. SIRT3 gene expression: a link between inherited mitochondrial DNA variants and oxidative stress. Gene 2012; 497: 323-9.
152. [152] Someya S, Xu J, Kondo K, et al. Age-related hearing loss in C57BL/6J mice is mediated by Bak-dependent mitochondrial apoptosis. Proc Natl Acad Sci USA 2009; 106: 19432-7.
153. [153] de Vivo DC. The expanding clinical spectrum of mitochondrial diseases. Brain Dev 1993; 15: 1-22.
154. [154] Maassen JA, van den Ouweland JM, t Hart LM, Lemkes HH. Maternally inherited diabetes and deafness: a diabetic subtype associated with a mutation in mitochondrial DNA. Horm Metab Res 1997; 29: 50-5.
155. [155] Rodenburg RJ. Biochemical diagnosis of mitochondrial disorders. J Inherit Metab Dis 2011; 34: 283-92.
156. [156] Hirschey MD, Shimazu T, Jing E, et al. SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome. Mol Cell 2011; 44: 1-14.
157. [157] Choudhary C, Kumar C, Gnad F, et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009; 325: 834-40.
158. [158] Stacpoole PW. The pyruvate dehydrogenase complex as a therapeutic target for age-related diseases. Aging Cell 2012; 11: 371-7.
159. [159] Wenz T, Diaz F, Spiegelman BM, Moraes CT. Activation of the PPAR/PGC-1alpha pathway prevents a bioenergetic deficit and effectively improves a mitochondrial myopathy phenotype. Cell Metab. 2008; 8: 249-56.
160. [160] Yatsuga S, Suomalainen A. Effect of bezafibrate treatment on lateonset mitochondrial myopathy in mice. Hum Mol Genet 2012; 21: 526-35.
161. [161] Bastin J, Aubey F, Rötig A, et al. Activation of peroxisome proliferator-activated receptor pathway stimulates the mitochondrial respiratory chain and can correct deficiencies in patients’ cells lacking its components. J Clin Endocrinol Metab 2008; 93: 1433-41.
162. [162] Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997; 275: 218-20.
163. [163] Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006; 5: 493-506.
164. [164] Wang J, Ho L, Zhao Z, et al. Moderate consumption of Cabernet Sauvignon attenuates A_ neuropathology in a mouse model of Alzheimer's disease. FASEB J 2006; 20: 2313-20.
165. [165] Kapoor VK, Dureja J, Chadha R. Synthetic drugs with anti-aging effects. Drug Discov Today 2009; 14: 899-904.
166. [166] Valenzano DR, Terzibasi E, Genade T, et al. Resveratrol prolongs lifespan and retards the onset of age-related markers in a short-live vertebrata. Current Biol 2006; 16: 296-300.
167. [167] Pallas M, Verdaguer E, Tajes M, et al. Modulation of AirTunes: new targets for anti-ageing. Recent Pat CNS Drug Discov 2008; 3: 61-9.
168. [168] Boily G, Seifert EL, Bevilacqua L, et al. Sirt1 regulates energy metabolism and response to caloric restriction in mice. PLoS One 2008; 3: e1759.
169. [169] Um JH, Park SJ, Kang H, et al. AMP-activated protein kinasedeficient mice are resistant to the metabolic effects of resveratrol. Diabetes 2010; 59: 554-6.
170. [170] Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006; 444: 337-42.
171. [171] Lagouge M, Argmann C, Gerhart-Hines Z, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1_. Cell 2006; 127: 1109-22.
172. [172] Ramadori G, Gautron L, Fujikawa T, et al. Central administration of resveratrol improves diet-induced diabetes. Endocrinology 2009; 150: 5326-33.
173. [173] Kim D, Nguyen MD, Dobbin MM, et al. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer’s disease and amyotrophic lateral sclerosis. EMBO J 2007; 26: 3169-79.
174. [174] Lu KT, Ko MC, Chen BY, et al. Neuroprotective effects of resveratrol on MPTP-induced neuron loss mediated by free radical scavenging. J Agric Food Chem 2008; 56: 6910-3.
175. [175] Blanchett F, Longpre G, Bureau M, et al. Resveratrol, a red wine polyphenol, protects dopaminergic neurons in MPTP-treated mice. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1243-50.
176. [176] Alvira D, Yeste-Velasco M, Folch J, et al. Comparative analysis of the effects of resveratrol in two apoptotic models: inhibition of complex I and potassium deprivation in cerebellar neurons. Neuroscience 2007; 147: 746-56.
177. [177] Chaturvedi RK, Beal MF. Mitochondria targeted therapeutic approaches in Parkinson's and Huntington's diseases. Mol Cell Neurosci 2013; 55: 101-14.
178. Randomized Trial of a Nutritional Supplement in Alzheimer's Disease. Available from: http://ClinicalTrial.gov.
179. [179] Nayagam VM, Wang X, Tan YC, et al. SIRT1 modulating compounds from high-throughput screening as anti-inflammatory and insulin-sensitizing agents. J Biomol Screen 2006; 11: 959-67.
180. [180] Vu CB, Bemis JE, Disch JS, et al. Discovery of imidazole [1,2-b] thiazole derivatives as novel SIRT1 activators. J Med Chem 2009; 52: 1275-83.
181. [181] Shindler KS, Ventura E, Rex TS, et al. SIRT1 activation confers neuroprotection in experimental optic neuritis. Invest Ophthalmol Vis Sci 2007; 48: 3602-9.
182. [182] Yamazaki Y, Usui I, Kanatani Y, et al. Treatment with SRT1720, a SIRT1 activator, ameliorates fatty liver with reduced expression of lipogenic enzymes in MSG mice. Am J Physiol Endocrinol Metab 2009; 297: 1179-86.
183. [183] Tein I. Carnitine transport: pathophysiology and metabolism of known molecular defects. J Inherit Metab Dis 2003; 26: 147-69.
184. [184] Mai A, Valente S, Meade S, et al. Study of 1,4-dihydropyridine structural scaffold: discovery of novel sirtuin activators and inhibitors. J Med Chem 2009; 52: 5496-504.
185. [185] Infante JP, Huszagh VA. Secondary carnitine deficiency and impaired docosahexaenoic acid synthesis: a common denominator in the pathophysiology of diseases of oxidative phosphorylation and beta-oxidation. FEBS Lett 2000; 468: 1-5.
186. [186] Hsu CC, Chuang YH, Tsai JL, et al. CPEO and carnitine deficiency overlapping in MELAS syndrome. Acta Neurol Scand 1995; 92: 252-5.
187. [187] DiMauro S, Hirano M, Schon EA. Approaches to the treatment of mitochondrial diseases. Muscle Nerve 2006; 34: 265-83.
188. [188] Marriage BJ, Clandinin MT, Macdonald IM, Glerum DM. Cofactor treatment improves ATP synthetic capacity in patients with oxidative phosphorylation disorders. Mol Genet Metab 2004; 81: 263-72.
189. [189] Liu J, Head E, Gharib AM, et al. Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/ or R-alpha-lipoic acid. Proc Natl Acad Sci USA 2002; 99: 2356-61.
190. [190] Liu J, Killilea DW, Ames BN. Age-associated mitochondrial oxidative decay: improvement of carnitine acetyltransferase substratebinding affinity and activity in brain by feeding old rats acetyl-Lcarnitine and/or R-alpha-lipoic acid. Proc Natl Acad Sci USA 2002; 99: 1876-81.
191. [191] Matthews RT, Yang L, Browne S, et al. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci USA 95: 8892-7.
192. [192] Freeman JM, Vining EP, Pillas DJ, et al. The efficacy of the ketogenic diet: a prospective evaluation of intervention in 150 children. Pediatrics 1998; 102: 1358-63.
193. [193] Freeman JM, Vining EP, Kossoff EH, et al. A blinded, crossover study of the efficacy of the ketogenic diet. Epilepsia 2009; 50: 322-5.
194. [194] Kang HC, Lee YM, Kim HD, et al. Safe and effective use of the ketogenic diet in children with epilepsy and mitochondrial respiratory chain complex defects. Epilepsia 2007; 48: 82-8.
195. [195] Joshi CN, Greenberg CR, Mhanni AA, Salman MS. Ketogenic diet in Alpers-Huttenlocher syndrome. Pediatr Neurol 2009; 40: 314-16.
196. [196] Roef MJ, de Meer K, Reijngoud DJ, et al. Triacylglycerol infusion improves exercise endurance in patients with mitochondrial myopathy due to complex I deficiency. Am J Clin Nutr 2002; 75: 237-44.
197. [197] Bough KJ, Wetherington J, Hassel, et al. Mitochondrial biogenesis in the anticonvulsant mechanism of the ketogenic diet. Ann Neurol 2006; 60: 223-35.
198. [198] Hancock CR, Han DH, Chen M, et al. High-fat diets cause insulin resistance despite an increase in muscle mitochondria. Proc Natl Acad Sci USA 2008; 105: 7815-20.
199. [199] Maalouf M, Rho JM, Mattson MP. The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies. Brain Res Rev 2009; 59: 293-15.
200. [200] Bough KJ, Wetherington J, Hassel B, et al. Mitochondrial biogenesis in the anticonvulsant mechanism of the ketogenic diet. Ann Neurol 2006; 60: 223-35.
201. [201] Maalouf M, Sullivan PG, Davis L, et al. Ketones inhibit mitochondrial production of reactive oxygen species production following glutamate excitotoxicity by increasing NADH oxidation. Neuroscience 2007; 145: 256-64.
202. [202] Santra S, Gilkerson RW, Davidson M, Schon EA. Ketogenic treatment reduces deleted mitochondrial DNAs in cultured human cells. Ann Neurol 2004; 56: 662-9.
203. [203] Ahola-Erkkila S, Carroll CJ, Peltola-Mjosund K, et al. Ketogenic diet slows down mitochondrial myopathy progression in mice. Hum Mol Genet 2010; 19: 1974-84.
204. [204] Mancuso M, Orsucci D, Volpi L, et al. Coenzyme Q10 in neuromuscular and neurodegenerative disorders. Current Drug Targets 2010; 11: 111-21.
205. [205] Haas RH, Parikh S, Falk MJ, et al. Mitochondrial disease: a practical approach for primary car physicians. Pediatrics 2007; 120: 1326-33.
206. [206] Lee CF, Liu CY, Chen SM, et al. Attenuation of UV-induced apoptosis by Coenzyme Q10 in human cells harboring large-scale deletion of mitochondrial DNA. Ann NY Acad Sci 2005; 1042: 429-38.
207. [207] Kooncumchoo P, Sharma S, Porter J, et al. Coenzyme Q10 provides neuroprotection in iron-induced apoptosis in dopaminergic neurons. J Mol Neurosci 2006; 28: 125-41.
208. [208] Chen RS, Huang CC, Chu NS. Coenzyme Q10 treatment in mitochondrial encephalomyopathies. Short-term double-blind, crossover study. Eur Neurol 1997; 37: 212-8.
209. [209] Di Giovanni S, Mirabella M, Spinazzola A, et al. Coenzyme Q10 reverses pathological phenotype and reduces apoptosis in familial CoQ10 deficiency. Neurology 2001; 57: 515-8.
210. [210] Beal MF. Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment. J Bioenerg Biomembr 2004; 36: 381-6.
211. [211] Ernster L, Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta 1995; 1271: 195-204.
212. [212] Haas RH, Parikh S, Falk MJ, et al. The in depth evaluation of suspected mitochondrial disease. Mol Genet Metab 2008; 94: 16-37.
213. [213] Smith RA, Porteous CM, Gane AM, et al. Delivery of bioactive molecules to mitochondria in vivo. Proc Natl Acad Sci USA 2003; 100: 5407-12.
214. [214] Murphy MP, Smith RA. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu Rev Pharmacol Toxicol 2007; 47: 629-56.
215. [215] Adlam VJ, Harrison JC, Porteous CM, et al. Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury. FASEB J 2005; 19: 1088-95.
216. [216] Graham D, Huynh NN, Hamilton CA, et al. Mitochondria-targeted antioxidant MitoQ10 improves endothelial function and attenuates cardiac hypertrophy. Hypertension 2009; 54: 322-8.
217. [217] Lim S, Rashid MA, Jang M, et al. Mitochondria-targeted antioxidants protect pancreatic _-cells against oxidative stress and improve insulin secretion in glucotoxicity and glucolipotoxicity. Cell Physiol Biochem 2011; 28: 873-86.
218. [218] Mercer JR, Yu E, Figg N, et al. The mitochondria-targeted antioxidant MitoQ decreases features of the metabolic syndrome in ATM+/-and ApoE-/-mice. Free Radic Biol Med 2012; 52: 841-9.
219. [219] McManus MJ, Murphy MP, Franklin JL. The mitochondriatargeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer's disease. J Neurosci 2011; 31: 15703-15.
220. [220] Ghosh A, Chandran K, Kalivendi SV, et al. Neuroprotection by a mitochondria-targeted drug in a Parkinson's disease model. Free Radic Biol Med 2010; 49: 1674-84.
221. [221] Chaturvedi RK, Beal MF. Mitochondria targeted therapeutic approaches in Parkinson's and Huntington's diseases. Mol Cell Neurosci 2013; 55: 101-14.
222. [222] Frantz MC, Wipf P. Mitochondria as a target in treatment. Environ Mol Mutagen 2010; 51: 462-75.
223. [223] KC S, Cárcamo JM, Golde DW. Vitamin C enters mitochondria via facilitative glucose transporter 1 (Glut1) and confers mitochondrial protection against oxidative injury. FASEB J 2005; 19: 1657-67.
224. [224] Peterson PL. The treatment of mitochondrial myopathies and encephalomyopathies. Biochim Biophys Acta 1995; 1271: 275-80.
225. [225] Komaki H, Nishigaki Y, Fuku N. Pyruvate therapy for Leigh syndrome due to cytochrome c oxidase deficiency. Biochim Biophys Acta 2010; 1800: 313-5.
226. [226] Acin-Perez R, Hoyos B, Zhao F, et al. Control of oxidative phosphorylation by vitamin A illuminates a fundamental role in mitochondrial energy homoeostasis. FASEB J 2010; 24: 627-36.
227. [227] Goldenberg PC, Steiner RD, Merkens LS, et al. Remarkable improvement in adult Leigh syndrome with partial cytochrome c oxidase deficiency. Neurology 2003; 60: 865-8.
228. [228] Marriage BJ, Clandinin MT, Macdonald IM, et al. Cofactor treatment improves ATP synthetic capacity in patients with oxidative phosphorylation disorders. Mol Genet Metab 2004; 81: 263-72.
229. [229] Liu C, Liang B, Wang Q, et al. Activation of AMPK-1_ alleviates endothelial cell apoptosis by increasing the expression of antiapoptotic proteins Bcl-2 and survivin. J Biol Chem 2010; 285: 15346-55.